Psoriasis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
For people with Psoriatic Arthritis:
- People diagnosed with peripheral or axial Psoriatic Arthritis using recognised medical classification systems, who also have signs of active disease confirmed by clinical assessment and ultrasound imaging (such as joint inflammation, tendon inflammation, heel/enthesis inflammation, or swollen fingers called dactylitis, measured using specific scoring tools)
- People whose condition is considered active enough, based on standard scoring systems, that a doctor has determined treatment with the drug Upadacitinib is appropriate under current medical guidelines, with a favourable benefit-risk assessment
- People aged 18 years or older
- People who are able to give informed consent as required by local ethics committee rules
For people with Rheumatoid Arthritis:
- People diagnosed with Rheumatoid Arthritis using the 2010 ACR/EULAR classification criteria
- People with active Rheumatoid Arthritis shown by a specific disease activity score (DAS28-CRP above 3.2) and at least one sign of inflammation in the hands or wrists confirmed by ultrasound
- People whose condition is considered suitable for treatment with Upadacitinib under current medical guidelines, with a favourable benefit-risk assessment in the treating doctor's opinion
- People aged 18 years or older
- People who are able to give informed consent as required by local ethics committee rules
Who may not be able to join:
- People who have any medical reason why Upadacitinib would not be safe for them, including: women who are pregnant or breastfeeding; people with an active infection; people with evidence of tuberculosis infection; people known to have HIV, hepatitis B, or hepatitis C; people with a current cancer diagnosis or a history of cancer in the last 5 years; people with a high risk of heart or blood vessel problems; people with a high risk of blood clots in the veins; or people with severe liver disease
- People who also have fibromyalgia syndrome, diagnosed using the 2016 ACR criteria
- People who are unable to give informed consent as required by local ethics committee rules
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Georgios Filippou, MD, Università degli Studi di Milano / IRCCS Ospedale Galeazzi-Sant'Ambrogio
Phone: 0039 0283502707
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Difference between US synovitis score
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.